References

1. Kobelt-Nguyen G, Gerdtham UG, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma. 1998;7(2): 95-104.

2. Kass MA, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713, 829-830.

3. Lavin MJ, et al. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990;108(11):1543-1548.

4. Broadway DC, et al. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112(11):1446-1454.

5. Chrai SS, et al. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci. 1974;63(3):333-338.

6. Kronfeld PC. The efficacy of combinations of ocular hypotensive drugs. A tonographic approach. Arch Ophthalmol. 1967;78(2):140-146.

7. Demailly P, Kerisel JB. [Combination of 2 percent pilocarpine—5 percent neosy-nephrine in the treatment of chronic and aphakic glaucoma]. Arch Ophthalmol Rev Gen Ophthalmol. 1967;27(7):683-696.

8. Krieglstein GK, Leydhecker W. [The pressure reducing effects of pilocarpin in combination with dipivalyl-epinephrine in glaucoma simplex]. Klin Monatsbl Augenheilkd. 1979;175(1):86-90.

9. Trotta N, O'Connor R. Efficacy of a combination solution of epinephrine and pilocarpine. Eye Ear Nose Throat Mon. 1971;50(9):350-352.

10. Knupp JA, et al. Combined timolol and epinephrine therapy for open angle glaucoma. Surv Ophthalmol. 1983;28(suppl):280-285.

11. Hovding G, Aasved H. Timolol/pilocarpine combination eye drops in open angle glaucoma and in ocular hypertension. A controlled randomized study. Acta Ophthalmol (Copenh). 1987;65(5):594-601.

12. Maclure GM, et al. Effect on the 24-hour diurnal curve of intraocular pressure of a fixed ratio combination of timolol 0.5% and pilocarpine 2% in patients with COAG not controlled on timolol 0.5%. Br J Ophthalmol. 1989;73(10):827-831.

13. Moriarty AP, Dowd TC, Trimble RB. Clinical experience with a fixed dose combination therapy of timolol and pilocarpine used twice daily in the management of chronic open angle glaucoma. Eye. 1994;8(pt 4):410-413.

14. Robin AL. Ocular hypotensive efficacy and safety of a combined formulation of be-taxolol and pilocarpine. Trans Am Ophthalmol Soc. 1996;94:89-103.

15. Clineschmidt CM, et al. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology. 1998;105(10):1952-1959.

16. Boyle JE, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology. 1998;105(10):1945-1951.

17. Strohmaier K, et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology. 1998;105(10):1936-1944.

18. Choudhri S, Wand M, Shields MB. A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol. 2000;130(6):832-833.

Gugleta K, Orgul S, Flammer J. Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzo-lamide, in Swiss ophthalmologists' offices. Curr Med Res Opin. 2003;19(4):330-335.

Bacharach J, Delgado MF, Iwach AG. Comparison of the efficacy of the fixed-combination timolol/dorzolamide versus concomitant administration of timolol and dorzolamide. J Ocul Pharmacol Ther. 2003;19(2):93-96.

Honrubia FM, Larsson LI, Spiegel D. A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma. Acta Ophthalmol Scand. 2002; 80(6):635-641.

Konstas AG, et al. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology. 2003;110(7):1357-1360.

Orzalesi N, et al. Comparison of latanoprost, brimonidine and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension. Acta Ophthalmol Scand. 2002; 236(suppl):55.

Fechtner RD, et al. Efficacy of the dorzolamide/timolol fixed combination versus la-tanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. J Ocul Pharmacol Ther. 2005;21(3):242-249.

Fechtner RD, et al. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (Cosopt) versus 0.005% (Xalatan) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand. 2004;82(1):42-48.

Day DG, et al. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2003;135(2):138-143. Sall KN, et al. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology. 2003;110(3):615-624.

Zabriskie N, Netland PA. Comparison of brimonidine/latanoprost and timolol/dor-zolamide: two randomized, double-masked, parallel clinical trials. Adv Ther. 2003; 20(2):92-100.

Alm A, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 1995;79(1):12-16.

Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol. 1994;78(12):899-902.

Orengo-Nania S, et al. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol. 2001; 132(6):860-868.

Higginbotham EJ, et al. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002;120(7):915-922. Pfeiffer N. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002;240(11):893-899.

34. Bucci MG. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group. J Glaucoma. 1999;8(1):24-30.

35. Konstas AG, et al. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol. 2002;133(6):753-757.

36. Stewart WC, et al. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol Scand. 2003;81(3):242-246.

37. Konstas AG, et al. Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%. Eye. 2004;18(12):1264-1269.

38. Shin DH, Feldman RM, Sheu WP. Efficacy and safety of the fixed combinations la-tanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology. 2004;111(2):276-282.

39. Barnebey HS, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140(1):1-7.

40. Hughes BA, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma. 2005;14(5):392-399.

41. Schuman JS, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/ timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2005;140(2):242-250.

42. Craven ER, et al. Brimonidine and timolol fixed-combination therapy versus mono-therapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2005;21(4):337-348.

43. Sherwood MB, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006;124(9): 1230-1238.

44. Goni FJ. 12-Week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol. 2005;15(5):581-590.

45. Realini T, Fechtner RD. 56,000 ways to treat glaucoma. Ophthalmology. 2002; 109(11):1955-1956.

This page intentionally left blank

Reducing Blood Pressure Naturally

Reducing Blood Pressure Naturally

Do You Suffer From High Blood Pressure? Do You Feel Like This Silent Killer Might Be Stalking You? Have you been diagnosed or pre-hypertension and hypertension? Then JOIN THE CROWD Nearly 1 in 3 adults in the United States suffer from High Blood Pressure and only 1 in 3 adults are actually aware that they have it.

Get My Free Ebook


Post a comment